Orphenadrine is a muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. MedsAcross supplies Orphenadrine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.
Source: US FDA prescribing information
Adults Two tablets per day, one in the morning and one in the evening.
Source: US FDA prescribing information
Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.
Source: US FDA prescribing information
Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle, ambulatory patients should therefore be cautioned accordingly.
Source: US FDA prescribing information
Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported.
Source: US FDA prescribing information
Store at 20°-25°C (68°-77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Orphenadrine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Orphenadrine 100 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Orphenadrine 60 mg/2 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 10 May 1957 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Orphenadrine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Orphenadrine and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Orphenadrine on 10 May 1957, according to Drugs@FDA.
No listed presentation of Orphenadrine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Orphenadrine is classified under ATC code M03BC01 (Orphenadrine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.